Last updated 3 months ago
SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM
534 patients around the world
Available in Chile, Argentina
Two study arms will be treated in 4-week cycles until disease progression, unacceptable
adverse events (AEs), participant request to discontinue therapy or any other reason,
whichever comes first.
Sanofi
8Research sites
534Patients around the world
This study is for people with
Multiple myeloma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Fundación Sanatorio Güemes - CABA, Buenos Aires
Recruiting
Clínica Adventista Belgrano - CABA - Buenos Aires
Recruiting
CEMIC - Hospital Universitario Sede Saavedra - CABA, Buenos Aires
Recruiting
Hospital Británico de Buenos Aires - CABA
Recruiting
Arbesú Hematología
Hospital Italiano de Buenos Aires - CABA, Buenos Aires
Recruiting
Hospital Italiano de La Plata
Recruiting
Instituto Médico Especializado Alexander Fleming - CABA, Buenos Aires
Recruiting
StudyIRAKLIA
SponsorSanofi
Study typeInterventional
Conditions
Multiple myeloma
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT05405166
